Navigation Links
TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Date:10/13/2009

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the number of multidrug-resistant (MDR) bacterial pathogens that have emerged and spread in recent years has dramatically reduced the utility of the current arsenal of antibiotics. Two such MDR pathogens in particular have been recognized as major threats to global public health, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). TAXIS is in the process of identifying and validating lead drug candidates that target MRSA and VRE with efficacies that are superior to current standards of therapeutic care.

"The compounds under investigation have great potential to treat a broad-spectrum of emerging, drug-resistant pathogens that represent large and growing public health and biodefense threats", said Gregory Mario, TAXIS' Chief Executive Officer. "We are excited to develop these further and move them closer to the clinic." The novel antimicrobial technology was discovered at the universities by Professors Daniel S. Pilch, Ph.D. (Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School) and Edmond J. LaVoie, Ph.D. (Department of Medicinal Chemistry, Rutgers University-Ernest Mario School of Pharmacy).


'/>"/>

Contact: Gregory G. Mario
GMario@TAXISPharma.com
609-240-8463
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
2. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
3. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
4. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Bacteria from sponges make new pharmaceuticals
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology: